Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report released on Wednesday,Benzinga reports. Chardan Capital currently has a $60.00 price target on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. B. Riley restated a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. Piper Sandler restated an “overweight” rating and issued a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 20th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.70.

Arrowhead Pharmaceuticals Trading Down 0.5 %

NASDAQ ARWR opened at $26.03 on Wednesday. The stock’s fifty day moving average price is $20.05 and its 200-day moving average price is $23.20. The company has a current ratio of 6.74, a quick ratio of 4.65 and a debt-to-equity ratio of 2.06. The stock has a market cap of $3.24 billion, a P/E ratio of -5.19 and a beta of 0.93. Arrowhead Pharmaceuticals has a 12 month low of $17.05 and a 12 month high of $39.83.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp increased its holdings in Arrowhead Pharmaceuticals by 42.5% during the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 354 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Meeder Asset Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 4,629.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 3,333 shares in the last quarter. nVerses Capital LLC bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth $96,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.